Literature DB >> 2251870

Polio immunity to killed vaccine: an 18-year follow-up.

M Böttiger1.   

Abstract

Two hundred and fifty children born in 1967 and vaccinated with killed polio vaccine in Sweden were followed for 18 years and tested for neutralizing antibodies against polio. All of them had demonstrable antibodies at the age of 18. Sixty-four children were tested in samples collected throughout the years. After a more marked fall of antibody titres during the first few years after vaccination, the decline levelled off to a mean decrease in titre of 0.05-0.10 log10 per year. In half of them, the routine vaccination comprising a fourth dose at 6 years of age was changed and this booster was postponed to the age of ten. The children given the booster dose at ten had significantly higher antibody levels at 18 years of age than those given it at six.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2251870     DOI: 10.1016/0264-410x(90)90244-g

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response.

Authors:  Kimberly M Thompson; Gregory S Wallace; Radboud J Duintjer Tebbens; Philip J Smith; Albert E Barskey; Mark A Pallansch; Kathleen M Gallagher; James P Alexander; Gregory L Armstrong; Stephen L Cochi; Steven G F Wassilak
Journal:  Public Health Rep       Date:  2012 Jan-Feb       Impact factor: 2.792

2.  Preeradication vaccine policy options for poliovirus infection and disease control.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Jong-Hoon Kim; Stephen L Cochi
Journal:  Risk Anal       Date:  2013-03-05       Impact factor: 4.000

Review 3.  Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Konstantin M Chumakov; Neal A Halsey; Tapani Hovi; Philip D Minor; John F Modlin; Peter A Patriarca; Roland W Sutter; Peter F Wright; Steven G F Wassilak; Stephen L Cochi; Jong-Hoon Kim; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-28       Impact factor: 4.000

4.  Schistosoma mansoni infection induces plasmablast and plasma cell death in the bone marrow and accelerates the decline of host vaccine responses.

Authors:  Fungai Musaigwa; Severin Donald Kamdem; Thabo Mpotje; Paballo Mosala; Nada Abdel Aziz; De'Broski R Herbert; Frank Brombacher; Justin Komguep Nono
Journal:  PLoS Pathog       Date:  2022-02-14       Impact factor: 6.823

Review 5.  Wanted, dead or alive: new viral vaccines.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Antiviral Res       Date:  2009-09-04       Impact factor: 5.970

Review 6.  Interrupting the transmission of wild polioviruses with vaccines: immunological considerations.

Authors:  Y Ghendon; S E Robertson
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

7.  Quantifying the impact of expanded age group campaigns for polio eradication.

Authors:  Bradley G Wagner; Matthew R Behrend; Daniel J Klein; Alexander M Upfill-Brown; Philip A Eckhoff; Hao Hu
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

Review 8.  Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis.

Authors:  Nicholas C Grassly
Journal:  J Infect Dis       Date:  2014-03-14       Impact factor: 5.226

9.  Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies.

Authors:  Sonia Resik; Alina Tejeda; Magile Fonseca; Carolyn Sein; Lai Heng Hung; Yenisleidys Martinez; Manuel Diaz; Hiromasa Okayasu; Roland W Sutter
Journal:  Trials Vaccinol       Date:  2015

10.  Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses.

Authors:  Siddhartha Kumar Bhaumik; Raveendra R Kulkarni; William C Weldon; Eduardo L V Silveira; Hasan Ahmed; Sivaram Gunisetty; Anmol Chandele; Rustom Antia; Harish Verma; Roland Sutter; Mark A Pallansch; M Steven Oberste; Francois Villinger; Walter Orenstein; Kaja Murali-Krishna
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.